From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA Confronts Its Limits in Push On Drug Pricing

from BioPharma DIVE

For years experts predicted biosimilars, the copycat versions of biologic medicines, would save the U.S. tens of billions in healthcare spending over the coming decades. So far, however, that hoped-for impact has yet to materialize. The Food and Drug Administration has approved 11 biosimilars, but only three are on the market — thanks to patent litigation that's tripped up entry of the rest. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063